Here, we report that on/fast-off activation of IFNβ in cancer is required for the therapeutic response to ICB, we dissect the contribution of IFNβ versus IFNα in the anti-tumour immune response, and we provide an example of time-dependent activation and inhibition of a drug target being required to achieve optimal anti-cancer effect. Here, IFNA1 is linked to cancer.